Advertisement

Moderna: COVID-19 booster targeting Omicron will be ready by August

By HealthDay News
Moderna's updated COVID-19 booster shot targets both Omicron and the original strain of the virus. File Photo by Keizo Mori/UPI | <a href="/News_Photos/lp/4c8cb913bfb22d29656451c731f75a40/" target="_blank">License Photo</a>
Moderna's updated COVID-19 booster shot targets both Omicron and the original strain of the virus. File Photo by Keizo Mori/UPI | License Photo

Moderna Inc. announced Wednesday that the revamped COVID-19 booster shot it has developed to fight Omicron and its subvariants should be ready for public use by August.

The company has been making shots of the vaccine, called mRNA-1273.214, before getting regulatory approval so it can be ready to ship doses out for the fall and winter, when health experts worry that there could be another wave of COVID-19.

Advertisement

"In the face of SARS-CoV-2's continued evolution, we are very encouraged that mRNA-1273.214, our lead booster candidate for the fall, has shown high neutralizing titers against the BA.4 and BA.5 [Omicron] subvariants, which represent an emergent threat to global public health," Moderna CEO Stephane Bancel said in a company news release.

"We will submit these data to regulators urgently and are preparing to supply our next generation bivalent [targeted to two variants] booster starting in August, ahead of a potential rise in SARS-CoV-2 infections due to Omicron subvariants in the early fall," Bancel added.

RELATED CDC approves COVID-19 vaccinations for children under 5

Already, the BA.4 and BA.5 subvariants account for 35% of all reported infections in the United States, up from 23% a week ago, the latest data from the U.S. Centers for Disease Control and Prevention shows.

Advertisement

The vaccine is targets both Omicron and the original strain of the virus, unlike the first vaccine which just targeted the original strain. In the latest data that Moderna released on Wednesday, the updated shot boosted antibodies against the BA.4/BA.5 subvariants by 5.4-fold above baseline in all participants regardless of prior infection, and by 6.3-fold in the subset of participants who had no detectable COVID-19 antibodies in their blood before getting their shot.

"We'd really like to be ready for the fall season later this year," Lavina Talukdar, head of investor relations at Moderna, said at a Goldman Sachs healthcare conference last week, CBS News reported. "In the Northern hemisphere, that's when we think that susceptibility to infections is going to go up higher just because we'll spend more time indoors."

RELATED Flu shots decline in states with low COVID-19 vaccination rates

The product could be ready to ship "toward the end of August, early September, October-ish time frame," Talukdar said at the time.

More information

The U.S. Centers for Disease Control and Prevention has more on COVID-19 vaccines.

RELATED More than three-fourths of U.S. teens have gotten HPV vaccinations

Copyright © 2022 HealthDay. All rights reserved.

Latest Headlines

Advertisement
Advertisement

Follow Us

Advertisement